AstraZeneca PLC (AZN)vsHims Hers Health Inc (HIMS)
AZN
AstraZeneca PLC
$186.68
-0.44%
HEALTHCARE · Cap: $294.17B
HIMS
Hims Hers Health Inc
$26.33
-5.66%
HEALTHCARE · Cap: $6.97B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 2402% more annual revenue ($58.74B vs $2.35B). AZN leads profitability with a 17.4% profit margin vs 5.5%. AZN appears more attractively valued with a PEG of 1.55. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
HIMS
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$186.68
$27.83 discount
Margin of Safety
+24.9%
Fair Value
$39.60
Current Price
$26.33
$13.27 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Every $100 of equity generates 25 in profit
Revenue surging 28.4% year-over-year
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Trading at 11.1x book value
Distress zone — elevated risk
5.5% margin — thin
Operating margin of 2.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : HIMS
The strongest argument for HIMS centers on Return on Equity, Revenue Growth. Revenue growth of 28.4% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : HIMS
The primary concerns for HIMS are Price/Book, Altman Z-Score, Profit Margin. A P/E of 59.9x leaves little room for execution misses. Debt-to-equity of 2.34 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a value stock while HIMS is a growth play — different risk/reward profiles.
HIMS carries more volatility with a beta of 2.31 — expect wider price swings.
HIMS is growing revenue faster at 28.4% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 50/100), backed by strong 17.4% margins. HIMS offers better value entry with a 24.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Hims Hers Health Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers with licensed healthcare professionals. The company is headquartered in San Francisco, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?